tbuckley/cabot-search huggingface dataset:
Augmented Proliferation of Human Alveolar Macrophages After Allogeneic Bone Marrow Transplantation
Authors: Koh Nakata, Hajime Gotoh, Junichi Watanabe, Takeshi Uetake, Iwao Komuro, Kazumi Yuasa, Shinya Watanabe, Ryuji Ieki, Hisashi Sakamaki, Hideki Akiyama, Shohji Kudoh, Makoto Naitoh, Hitoshi Satoh, Kaoru Shimada
Journal: Blood (1999)
Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation
Authors: Jared D. Miller, Konstantinos N. Aronis, Jonathan Chrispin, Kaustubha D. Patil, Joseph E. Marine, Seth S. Martin, Michael J. Blaha, Roger S. Blumenthal, Hugh Calkins
Journal: Journal of the American College of Cardiology (2015)

Classically, the 3 pillars of atrial fibrillation (AF) management have included anticoagulation for prevention of thromboembolism, rhythm control, and rate control. In both prevention and management of AF, a growing body of evidence supports an increased role for comprehensive cardiac risk factor modification (RFM), herein defined as management of traditional modifiable cardiac risk factors, weight loss, and exercise. In this narrative review, we summarize the evidence demonstrating the importance of each facet of RFM in AF prevention and therapy. Additionally, we review emerging data on the importance of weight loss and cardiovascular exercise in prevention and management of AF.
Production of proinflammation cytokines and mean pulmonary arterial pressure in COPD
Authors: Svetlana Soodaeva, Igor Klimanov, Timur Li, Marina Boldina, Larisa Postnikova, Nailja Kubysheva
Journal: European Respiratory Journal (2013)

Background:  Proinflammation cytokine s  play a role in neutrophilic inflammation in the airway and induce pulmonary fibrosis in COPD.   The aim  of the study was to analyse the levels of TNF-α, IL-17, IL-18 in the sera of patients with COPD in order to evaluate the role of TNF-α, IL-17, IL-18 production in the pulmonary hypertension of patients with COPD.   Methods:  In total, 42 COPD patients (37 males and 5 females) 61.2 ± 8,6 years old and 10 healthy volunteers were monitored. COPD severity: GOLD I stage - 8%; II stage - 12%; III stage - 7%; IV stage - 15%. TNF-α, IL-17 and IL-18 levels were measured by immunoassay in serum. The mean pulmonary arterial pressure (mPAP) was detected by Doppler-echocardiography.   Results:  Levels of TNF-α, IL-17 and IL-18 in serum were significantly higher in COPD patients compared to healthy controls. The progressing increase of inflammation biomarkers concentrations in blood in COPD patients combined with stages of COPD. TNF-α serum levels in COPD IV stage patients were higher than patients with COPD I stage (3.25±0.14 pg/ml vs. 1.34±0.07 pg/ml; p  0.001). IL-17 and IL-18 blood concentrations in COPD IV stage patients were higher than COPD GOLD I stage (3.81±0.17 pg/ml vs. 2.38±0.04 pg/ml; p  0.01 and 198.4±24.9 pg/ml vs. 146.1±13.7 pg/ml; p=0.04). In COPD patients, there was a significant (p sp =0.61; p sp =0.68; p Conclusions:  Our results may indicate that an increased cytokines serum levels (TNF-α, IL-17 and IL-18) may induce of pulmonary hypertension in COPD.
IMPAIRMENT OF AORTIC ELASTIC PROPERTIES AND ELEVATED CIRCULATING LEVELS OF TRANSFORMING GROWTH FACTOR-BETA IN SUBJECTS WITH REPAIRED COARCTATION OF AORTA
Authors: Styliani V. Brili, Alexis Antonopoulos, Evangelos Oikonomou, Aimilios Kalampogias, Konstantinos Mourouzis, Symeon Mavroudeas, Marina Zaromytidou, Evangelos K. Ekonomou, Gerasimos Siasos, Petros Nihoyannopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2016)
ALK7 protects against pathological cardiac hypertrophy in mice
Authors: He Huang, Yanhong Tang, Gang Wu, Yang Mei, Wanli Liu, Xiaoxiong Liu, Nian Wan, Yu Liu, Congxin Huang
Journal: Cardiovascular Research (2015)

Activin receptor-like kinase 7 (ALK7), one of the type I transforming growth factor-β receptors, is expressed in various tissues, including the heart. However, the participation of ALK7 in the regulation of cardiac hypertrophy has not yet been studied. Here, we sought to determine the regulatory role and underlying mechanisms of ALK7 in cardiac hypertrophy. We performed aortic banding (AB) in ALK7-knockout mice, cardiac-specific ALK7-transgenic mice, and the wild-type littermates of these mice. Cardiac hypertrophy was evaluated using pathological analysis, echocardiographic measurement, haemodynamic measurement, and molecular analysis. Our results revealed that ALK7 disruption led to an aggravated cardiac hypertrophic response that was accompanied by increased cardiac fibrosis and reduced contractile function, whereas cardiac-specific ALK7 overexpression exhibited the opposite phenotype in response to pressure overload. Similarly, ALK7 protected against angiotensin II-induced cardiomyocyte hypertrophy in vitro. Mechanistically, we demonstrated that ALK7-dependent cardioprotection was mediated largely through inhibition of the MEK–ERK1/2 signalling pathway. Our data suggest that ALK7 acts as a novel regulator of pathological cardiac hypertrophy via the negative regulation of MEK–ERK1/2 signalling and may serve as a potential therapeutic target for pathological cardiac hypertrophy.
Beneficial effects of non-invasive positive pressure ventilation before vertebral arthrodesis in patients with Duchenne muscular dystrophy
Authors: Jessica Taytard, Raphaël Vialle, Michelle Mayer, Laurent Servais, Harriet Corvol, Annick Clement, Guillaume Aubertin
Journal: European Respiratory Journal (2014)

Introduction : Vertebral surgery for Duchenne muscular dystrophy (DMD) patients remains a challenge. The objective of this study was to analyse the postoperative respiratory outcome, according to the use of preoperative non-invasive positive pressure ventilation (NPPV).

Patients and Methods : Retrospective study including 13 DMD patients who benefited from a vertebral arthrodesis in a tertiary referral hospital between January 2010 and June 2013. Median age was 13 years old (11.6-16.2) at time of surgery. The surgery was a posterior arthrodesis without thoracotomy. We compared 2 groups of patients with or without preoperative NPPV: NPPV group (8 patients) and non NNPV group (5 patients). We studied preoperative and postoperative pulmonary function test and respiratory muscle strength in these 2 groups. We analysed two main parameters: durations of postoperative invasive ventilation (IV) and hospitalisation in intensive care unit (ICU).

Results : In the NPPV and non NPPV group, median forced vital capacity was respectively of 37% (29-57%) and 50% (59-42%). Total lung capacity was respectively of 61 % (71-47%) and 68 % (80-49%). There was no statistical difference as for the two main parameters studied. But we showed in NPPV patients a tendency towards shorter postoperative IV (1 vs 2 days) and ICU stay (2 vs 3 days). One patient, who did not benefit from preoperative NPPV, had a postoperative pulmonary atelectasis.

Conclusion : For DMD patients with severe scoliosis, preoperative NPPV tends to reduce both postoperative IV and ICU stay durations after the vertebral arthrodesis, even for patients with more severely altered pulmonary functions.
Androgen Deprivation and Four Courses of Fixed-Schedule Suramin Treatment in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Southwest Oncology Group Study
Authors: Maha Hussain, Emily I. Fisher, Daniel P. Petrylak, John O’Connor, David P. Wood, Eric J. Small, Mario A. Eisenberger, E. David Crawford
Journal: Journal of Clinical Oncology (2000)

PURPOSE: To assess the feasibility of administering a combination of suramin and hydrocortisone in addition to androgen deprivation in a cooperative group setting; to assess the feasibility of treatment with multiple courses of suramin; and to assess progression-free and overall survival in patients with newly diagnosed metastatic prostate cancer who underwent such treatment. PATIENTS AND METHODS: Patients with newly diagnosed metastatic prostate cancer who had adequate hematologic, hepatic, renal, neurologic, and coagulation parameters were treated by combined androgen deprivation and suramin plus hydrocortisone. Suramin was administered on a 78-day fixed dosing schedule (one cycle), and suramin treatment cycles were repeated every 6 months for a total of four cycles. The statistical design was developed on the basis of the feasibility of administering suramin, as judged by the number of patients who developed neurotoxicity of grade 3 or higher or by treatment interruption of 4 weeks or longer due to any persistent suramin-related toxicity. RESULTS: Of the 62 patients enrolled onto the study between August 1994 and January 1997, 59 were eligible and assessable for toxicity on the first cycle. Thirty-two (54%) of 59 patients received a second cycle, 13 (22%) of 59 patients received a third cycle, and only five patients (8%) received a fourth cycle. During the first cycle, 27 patients were removed from the study: 17 because of toxicity, five because of disease progression, two who had died, and three because of other reasons. There was one therapy-related death. Grade 4 toxicities were noted in 11 and three patients during first and second courses, respectively. Neurotoxicity of grade 3 or higher was observed in nine and seven patients during the first and second cycles, respectively. Fifteen patients had treatment interruptions of 4 weeks or longer. Overall, only 54% (95% confidence interval, 41% to 67%) of the patients demonstrated acceptable limits of toxicity. CONCLUSION: Suramin plus hydrocortisone and androgen deprivation has limited applicability in the treatment of patients with newly diagnosed metastatic prostate cancer.
Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling
Authors: Rose Ann Padua, Petra Gorombei, Stéphanie Beurlet, Nader Omidvar, Satyananda Patel, Laura Guerenne, Carole Le Pogam, Niclas Setterblad, Pierre de la Grange, Fabien Guidez, Christophe Le Boeuf, Anne Janin, Maria-Elena Noguera, Laure Sarda-Mantel, Pascal Merlet, Robert West, Marika Pla, Pierre Fenaux, Patricia Krief, Christine Chomienne
Journal: Blood (2014)
Exercise and the Prevention of Low Back Pain
Authors: Timothy S. Carey, Janet K. Freburger
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study.
Authors: R B Livingston, J G Mira, T T Chen, M McGavran, J J Costanzi, M Samson
Journal: Journal of Clinical Oncology (1984)

The Southwest Oncology Group entered 453 patients with extensive small cell carcinoma into a combined modality treatment program, involving a randomized comparison of three different chemotherapy regimens for remission induction, and of maintenance chemotherapy alone versus maintenance treatment with cycles of reinduction added at six and 12 months. In addition, there was systematic comparison of diagnosis by institutional pathologist versus review panel pathologist. No difference was observed among the three different induction arms with respect to the incidence of response to treatment (61%), complete response (16%), or survival duration (median, 31 weeks). Neither overall response rate nor survival are superior to previous results. However, patients who achieved a complete response demonstrated significant survival benefit if they were in the group who received reinduction chemotherapy, as opposed to maintenance alone. This observation may apply most importantly to patients with small cell lung cancer of limited extent, for whom complete response is achieved in a majority. Agreement of institutional and review panel pathologists on the diagnosis of small cell lung cancer was observed in 94% of reviewed cases. A final observation is that the omission of chest irradiation results in a dramatic increase in the incidence of initial relapse at the primary tumor site. This suggests that future studies will need to use better therapy for local control in responding patients.
Headliners: Liver Cancer: Hepatitis B Virus Mutation Predicts Liver Cancer.
Authors: Jerry Phelps
Journal: Environmental Health Perspectives (2004)

Kuang SY, Jackson PE, Wang JB, Lu PX, Munoz A, Qian GS, Kensler TW, Groopman JD. 2004. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA 101:3575–3580.

Liver cancer is the fifth most prevalent form of cancer worldwide, causing more than 500,000 deaths annually, according to the World Health Organization. Exposure to the hepatitis B virus (HBV) is a major risk factor in the development of liver cancer. Now a team including NIEHS grantees Alvaro Munoz, John D. Groopman, and Thomas W. Kensler, all of the Johns Hopkins Bloomberg School of Public Health, has identified a biomarker that may predict future cases of liver cancer in HBV carriers.

Previous work by members of this team has shown that HBV exposure causes a 7-fold increase in risk. Exposure to aflatoxin, a mold product commonly found in peanuts and grains, increases the risk of liver cancer by 3.5 times. Combined exposure to these two agents results in a remarkable 60-fold increase in the risk of developing liver cancer. This is an especially troubling public health problem in China, where HBV and aflatoxin exposures are both very high.

In the current study, the researchers examined the prevalence a particular HBV mutation in the plasma and tumors of liver cancer patients living in Qidong, China. Initial studies determined that about three-fourths of the tumors from an initial group of 70 patients contained the mutation. In a second group of 15 liver cancer patients chosen from a cohort of high-risk individuals, the investigators determined that about half had detectable levels of the HBV mutation in their blood several years before the cancer appeared.

These findings suggest that detection of the mutated HBV in the blood is an early warning sign of subsequent liver cancer development, and suggest its use as an intermediate end point in prevention and intervention trials. –Jerry Phelps
Expansion of activated regulatory T cells inversely correlates with clinical severity in septic neonates
Authors: Eleonora Timperi, Laura Folgori, Donato Amodio, Maia De Luca, Sara Chiurchiù, Silvia Piconese, Silvia Di Cesare, Ilenia Pacella, Carmela Martire, Giulia Bonatti, Seila Perrone, Terenzio Boni, Genni Enza Marcovecchio, Antonino Reale, Francesco Parisi, Andrea Dotta, Vincenzo Barnaba, Paolo Rossi
Journal: Journal of Allergy and Clinical Immunology (2016)
Abstract 18104: Chagas Disease is not Independently Associated with Atrial Fibrillation in Patients with Cardiomyopathy
Authors: Rhanderson N Cardoso, Daniel Garcia, Gilson Fernandes, Francisco Macedo, Mohammad Ansari, Raul D Mitrani
Journal: Circulation (2014)

Introduction: Chagas Disease (CD) has been associated with an increased incidence of stroke, which may ultimately be due to an increased prevalence of atrial fibrillation (AF). Observational studies support this possibility, but data is conflicting. Furthermore, it is unknown if CD represents an independent risk factor for AF when compared to other cardiomyopathies. Hypothesis: CD is significantly associated with an increased prevalence of AF when compared to other cardiomyopathies. Methods: PubMed, EMBASE, Cochrane Central and Latin American databases were searched for studies that directly compared the prevalence of AF in CD patients to a non-CD group. Odds-ratios were computed using a random-effects model due to anticipated heterogeneity. Subanalyses were performed on studies in which both the control group and CD patients had (1) cardiomyopathy and (2) heart failure. Results: A total of 18 studies and 10,724 patients were included, of whom 4,216 (39.3%) had a positive serology for CD. In the pooled data, AF was significantly more prevalent among the CD group (OR 1.69; 95% CI 1.24-2.30; p&lt;0.001; Figure 1). However, no significant difference was observed between groups when the analysis included only patients with cardiomyopathy (11 studies; OR 1.33; 95% CI 0.94-1.89; p=0.11; Figure 2A) and heart failure (6 studies; OR 1.03; 95% CI 0.75-1.43; p=0.85; Figure 2B). Conclusions: Our meta-analysis suggests that in patients with cardiomyopathy or heart failure, Chagas Disease etiology is not independently associated with atrial fibrillation.
P0827 : A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: Findings from a us payer database
Authors: J.B. Forlenza, J. Fortier, F. Laliberté, P. Lefebvre, N. Tandon
Journal: Journal of Hepatology (2015)
Abstract 3002: Left Ventricular Diameter Predicts Recovery in Acute Cardiomyopathy: Results of the IMAC 2 Trial
Authors: Randall C Starling, Leslie T Cooper, G W Dec, John Boehmer, Peter Liu, Daniel Pauly, John Gorscan, Masaki Tanabe, Kevin Kip, Dennis M McNamara
Journal: Circulation (2007)

Introduction : The incidence of spontaneous clinical improvement in acute cardiomyopathy (ACM) patients treated with evidence based medical therapy is unknown. We hypothesized that pts without LV dilatation at presentation would have the greatest potential for recovery of ejection fraction (EF). Methods: A multi-center NHLBI sponsored trial, Intervention in Myocarditis and Acute Cardiomyopathy II (IMAC 2) was designed to study the clinical course of ACM and the mechanisms associated with outcomes. A clinical, echocardiography, and genetics core lab are established. Results: 15 centers have enrolled 215 pts, mean age 45 ± 14 yrs, 34% female, NYHA class I–IV% 18/54/21/7, baseline EF 0.25 ± 0.09. Therapy included 80% beta blockers and 92% ACE or ARB treated. All patients enrolled had symptoms for ≤ 6 mos and were diagnosed with acute, idiopathic cardiomyopathy or myocarditis. Baseline and 6 mo echoes in 140 pts reviewed by the core lab demonstrated increased ejection fraction (EF): 0.25 ± 0.09 to 0.40 ± 0.11 p&lt;0.001; mean increase 0.15 ± 0.10. Recovery in EF from baseline to 6 mos was related to LVEDD at baseline as shown in the Figure . Kaplan Meier survival n=207 at 1 and 2 years 96% and 94% and transplant free survival at 1 and 2 yrs 92% and 91%. Conclusions: Results of IMAC 2 reveal a marked spontaneous improvement in EF over 6 months, greatest in those with non-dilated LVEDD at baseline, and excellent overall survival in ACM pts treated with evidence based therapies.
A randomized phase III study of sox (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer.
Authors: Y. S. Park, H. Y. Lim, J. Lee, T. W. Kim, J. Lee, Y. S. Hong, S. Y. Kim, J. Y. Baek, J. H. Kim, K. Lee, I. Chung, S. Cho, K. H. Lee, S. J. Shin, H. J. Kang, D. Shin, S. J. Jo, J. W. Lee
Journal: Journal of Clinical Oncology (2011)

3524 Background: A regimen consisting of capecitabine and oxaliplatin (COX) is widely used in Korea in the first-line treatment of metastatic colorectal cancer (MCRC). S-1 may have considerable activity compared with capecitabine. Phase I and II studies showed that S-1 plus oxaliplatin (SOX) might have at least comparable activity with COX in MCRC. The aim of study was to evaluate whether SOX is noninferior to COX in terms of progression free survival (PFS) in patients previously untreated with systemic therapy for MCRC. Our hypothesis was that SOX is non-inferior to COX if the upper limit of 95% confidence interval for hazard ratio (HZ) between those two arms is below 1.4327, which comes from the non-inferiority margin of 13% in progress-free survival at 15 months. Methods: This study was a randomized, two-arm, non-inferiority, phase III comparison of SOX versus COX. Patients with MCRC were stratified according to primary site (colon vs. rectum), previous treatment (adjuvant therapy vs. none) and status of disease (measurable vs. evaluable disease). SOX (S-1: 80 mg/m2/day D1-14, oxaliplatin: 130 mg/m2/day D1) and COX (capecitabine: 2,000 mg/m2/day D1-14, oxaliplatin: 130 mg/m2/day D1) were repeated every 3 weeks as first-line treatment. Results: Between May 2008 and September 2009, a total of 345 patients were enrolled (SOX = 172; COX = 173) from 11 centers in Korea. In the intent-to-treat population, median PFS was 7.1 months in SOX arm versus 6.3 months in COX arm (HZ=0.809 [0.633-1.033], p=0.087). Overall survival was 20.9 and 19.9 months with SOX and COX respectively (HZ=0.897 [0.638-1.260], p=0.530). Overall response rate was 48.9 % and 34.2 % with SOX and COX, respectively (Odds=1.81.[1.157-2.839], p=0.009). Toxicity profiles were not different. Conclusions: We conclude that SOX is non-inferior in terms of efficacy to COX in the first-line treatment of MCRC. Independent review is ongoing for final conclusion.